The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Feb. 27, 2:31 PM

Slide #25. Adverum Biotechnologies, Inc Secondary Offering

Company: Adverum Biotechnologies, Inc (NASDAQ:ADVM)
Date announced: 2/10/2020
Secondary Offering Details: Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $100 million of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering will be sold by Adverum Biotechnologies. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. Co. develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Co.'s main capabilities include clinical development, vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. Co. is conducting a clinical trial for its gene therapy candidate ADVM-022, AAV.7m8-aflibercept, for the treatment of wet age-related macular degeneration.

ADVM SEC Filing Email Alerts Service

Open the ADVM Page at The Online Investor »

Company Name: 
Adverum Biotechnologies Inc
Website: 
www.adverum.com
Sector: 
Biotechnology
Number of ETFs Holding ADVM: 
20
Total Market Value Held by ETFs: 
$62.79M
Total Market Capitalization: 
$849.00M
% of Market Cap. Held by ETFs: 
7.40%
 

Open the ADVM Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Buy (3.33 out of 4)
58th percentile
(ranked higher than approx. 58% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.